Blog
RSS FeedPosted by Michael Wonder on 25 Dec 2025
Health Canada approves Tevimbra (tislelizumab for injection) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma
23 December 2025 - Approval supported by results of the RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival ...
Posted by Michael Wonder on 20 Dec 2025
Knight Therapeutics announces Health Canada approval for Wynzora to treat psoriasis vulgaris
18 December 2025 - Knight Therapeutics announced today that Health Canada has approved Wynzora, a white uniform cream containing 0.05 ...
Posted by Michael Wonder on 19 Dec 2025
Health Canada authorises TNKase (tenecteplase) for the treatment of acute ischaemic stroke
17 December 2025 - The approval marks the first new stroke treatment authorised in nearly 27 years, offering an additional ...
Posted by Michael Wonder on 18 Dec 2025
Alnylam announces Health Canada approval of Amvuttra (vutrisiran), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
16 December 2025 - Alnylam Canada is pleased to announce that Health Canada has issued a Notice of Compliance authorising Amvuttra ...
Posted by Michael Wonder on 18 Dec 2025
Chiesi Global Rare Diseases announces Health Canada approval of Elfabrio (pegunigalsidase alfa) for Fabry disease
16 December 2025 - Chiesi Global Rare Diseases today announced the Health Canada approval of Elfabrio (pegunigalsidase alfa) for the treatment ...
Posted by Michael Wonder on 17 Dec 2025
Wegovy (semaglutide injection) receives conditional marketing authorisation from Health Canada as the first and only treatment for adults with non-cirrhotic MASH, a serious liver disease
15 December 2025 - Novo Nordisk announced today that Health Canada has issued marketing authorisation with conditions (Notice of Compliance ...
Posted by Michael Wonder on 12 Dec 2025
PTC Therapeutics announces Health Canada approval of Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria
10 December 2025 - PTC Therapeutics Canada announced that Health Canada has approved Sephience (sepiapterin) for the treatment of children and ...
Posted by Michael Wonder on 10 Dec 2025
Biogen receives Health Canada authorisation for Zurzuvae (zuranolone), the first and only treatment indicated for adults with postpartum depression in Canada
9 December 2025 - Biogen Canada today announced that Health Canada has issued a Notice of Compliance for Zurzuvae (zuranolone) ...
Posted by Michael Wonder on 03 Dec 2025
Anzupgo (delgocitinib cream) now available in Canada for adult patients living with moderate to severe chronic hand eczema
2 December 2025 - Leo Pharma is pleased to announce the availability of Anzupgo (delgocitinib cream) across Canada for adults ...
Posted by Michael Wonder on 28 Nov 2025
Celltrion receives Health Canada approval for Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg)
27 November 2025 - The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global ...
Posted by Michael Wonder on 19 Nov 2025
Esperion partner HLS Therapeutics announces approval of Nilemdo for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease
18 November 2025 - Esperion today announced that HLS Therapeutics, the Company’s partner in Canada for the development and commercialization ...
Posted by Michael Wonder on 18 Nov 2025
Lupron Depot new strength receives Health Canada approval for the treatment of advanced prostate cancer
17 November 2025 - AbbVie announced today that a new 6 month 45 mg Lupron Depot (leuprolide acetate for extended release ...
Posted by Michael Wonder on 14 Nov 2025
Arcutis Canada announces Health Canada approval of Zorvye 0.3% topical foam, the first steroid-free topical foam for scalp and body psoriasis, for adults and adolescents ages 12 and older
13 November 2025 - Approval supported by pivotal Phase 3 and Phase 2 data demonstrating rapid improvement in skin clearance and ...
Posted by Michael Wonder on 13 Nov 2025
Marius Pharmaceuticals expands global footprint with Health Canada approval of Kyzatrex (testosterone undecanoate) CIII capsules
12 November 2025 - Marius Pharmaceuticals today announced that Health Canada has approved Kyzatrex (testosterone undecanoate) CIII capsules. ...
Posted by Michael Wonder on 06 Nov 2025
argenx announces Vvygart SC pre-filled syringe for self-Injection in chronic inflammatory demyelinating polyneuropathy authorised for sale by Health Canada
5 November 2025 - argenx today announced that Health Canada has issued a Notice of Compliance authorising Vvyvart SC (efgartigimod alfa ...